{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:27:45Z","timestamp":1792794465081,"version":"4.5.0"},"reference-count":105,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T00:00:00Z","timestamp":1626048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Medtronic Japan Co., Ltd","id":[{"id":"https:\/\/ror.org\/031tfsa37","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Debulking surgery, also called cytoreductive surgery, is a resection of the tumor as much as possible and an intended incomplete resection for unresectable malignant tumors. Since the most important principle in surgical oncology is complete R0 resection, debulking surgery goes against the basic principle and obscures the concept of operability. However, debulking surgery has been advocated for various types of advanced malignant tumors, including gynecological cancers, urological cancers, gastrointestinal cancers, breast cancers and other malignancies, with or without adjuvant therapy. Positive data from randomized trials have been shown in subsets of ovarian cancer, renal cell carcinoma, colorectal cancer and breast cancer. However, recent trials for renal cell carcinoma, colorectal cancer and breast cancer have tended to show controversial results, mainly according to the survival improvement of nonsurgical systemic therapy alone. On the other hand, debulking surgery still has a therapeutic role for slow-growing and borderline malignant tumors, such as pseudomyxoma peritonei and thymomas. The recent understanding of tumor heterogeneity and clonal evolution responsible for malignancy and drug resistance indicates that select patients may obtain prolonged survival by the synergistic effect of debulking surgery and novel systemic therapy. This review aimed to describe the current status and evidence of debulking surgery in a cross-organ manner and to discuss future perspectives in the current era with advances in systemic therapy.<\/jats:p>","DOI":"10.1093\/jjco\/hyab107","type":"journal-article","created":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T15:15:28Z","timestamp":1624288528000},"page":"1349-1362","source":"Crossref","is-referenced-by-count":27,"title":["Debulking surgery for malignant tumors: the current status, evidence and future perspectives"],"prefix":"10.1093","volume":"51","author":[{"given":"Tomoyuki","family":"Hishida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyohei","family":"Masai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Kaseda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Asakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisao","family":"Asamura","sequence":"additional","affiliation":[{"name":"Division of Thoracic Surgery, Department of Surgery, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,7,12]]},"reference":[{"key":"2021083104310140900_ref1","volume-title":"Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health","author":"Miller-Keane","year":"2003","edition":"7th"},{"key":"2021083104310140900_ref2","author":"National Cancer Institute [Internet]"},{"key":"2021083104310140900_ref3","volume-title":"Principles of Surgical Oncology. Cancer Concepts: A Guidebook for the Non-Oncologist","author":"Giles","year":"2016"},{"key":"2021083104310140900_ref4","first-page":"577","article-title":"Surgical debulking of tumors","volume":"155","author":"Silberman","year":"1982","journal-title":"Surg Gynecol Obstet"},{"key":"2021083104310140900_ref5","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/ncponc0560","article-title":"The Norton-Simon hypothesis: designing more effective and less toxic chemotherapeutic regimens","volume":"3","author":"Simon","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"key":"2021083104310140900_ref6","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1001\/archsurg.143.4.352","article-title":"First-line chemotherapy vs. bowel tumor resection plus chemotherapy for patients with unresectable synchronous colorectal hepatic metastases","volume":"143","author":"Galizia","year":"2008","journal-title":"Arch Surg"},{"key":"2021083104310140900_ref7","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s00268-009-0366-y","article-title":"Meta-analysis of survival of patients with stage IV colorectal cancer managed with surgical resection versus chemotherapy alone","volume":"34","author":"Stillwell","year":"2010","journal-title":"World J Surg"},{"key":"2021083104310140900_ref8","first-page":"1","article-title":"Clinical and histologic studies of ovarian carcinoma. Long-term follow-up of 990 cases","volume":"37","author":"Aure","year":"1971","journal-title":"Obstet Gynecol"},{"key":"2021083104310140900_ref9","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0039-6109(16)41440-4","article-title":"Intensive surgical and chemotherapeutic management of advanced ovarian cancer","volume":"58","author":"Griffiths","year":"1978","journal-title":"Surg Clin North Am"},{"key":"2021083104310140900_ref10","doi-asserted-by":"crossref","DOI":"10.6004\/jnccn.2019.0039","article-title":"NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019","volume-title":"J Natl Compr Canc Netw","author":"Armstrong","year":"2019"},{"key":"2021083104310140900_ref11","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1200\/JCO.2006.10.2517","article-title":"Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Winter","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021083104310140900_ref12","article-title":"Optimal primary surgical treatment for advanced epithelial ovarian cancer","volume":"2011","author":"Elattar","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"2021083104310140900_ref13","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJM199503093321002","article-title":"The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer","volume":"332","author":"Burg","year":"1995","journal-title":"N Engl J Med"},{"key":"2021083104310140900_ref14","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/jjco\/hym145","article-title":"Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III\/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0602","volume":"38","author":"Onda","year":"2008","journal-title":"Jpn J Clin Oncol"},{"key":"2021083104310140900_ref15","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N Engl J Med"},{"key":"2021083104310140900_ref16","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet"},{"key":"2021083104310140900_ref17","doi-asserted-by":"crossref","DOI":"10.1136\/ijgc-2020-001640","article-title":"Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850)","author":"Fagotti","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"2021083104310140900_ref18","doi-asserted-by":"crossref","first-page":"6000","DOI":"10.1200\/JCO.2020.38.15_suppl.6000","article-title":"Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: Final analysis of AGO DESKTOP III\/ENGOT-ov20","volume":"38","author":"Bois","year":"2020","journal-title":"J Clin Oncol"},{"key":"2021083104310140900_ref19","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1006\/gyno.1994.1038","article-title":"Surgical stage IV endometrial carcinoma: a study of 47 cases","volume":"52","author":"Goff","year":"1994","journal-title":"Gynecol Oncol"},{"key":"2021083104310140900_ref20","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1245\/s10434-009-0892-8","article-title":"Endometrial carcinoma with extra-abdominal metastasis: improved prognosis following cytoreductive surgery","volume":"17","author":"Ueda","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"2021083104310140900_ref21","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/sj.bjc.6605157","article-title":"Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment?","volume":"101","author":"Vandenput","year":"2009","journal-title":"Br J Cancer"},{"key":"2021083104310140900_ref22","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.eururo.2011.06.049","article-title":"The epidemiology of renal cell carcinoma","volume":"60","author":"Ljungberg","year":"2011","journal-title":"Eur Urol"},{"key":"2021083104310140900_ref23","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMoa003013","article-title":"Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer","volume":"345","author":"Flanigan","year":"2001","journal-title":"N Engl J Med"},{"key":"2021083104310140900_ref24","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S0140-6736(01)06103-7","article-title":"Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial","volume":"358","author":"Mickisch","year":"2001","journal-title":"Lancet"},{"key":"2021083104310140900_ref25","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1803675","article-title":"Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma","volume":"379","author":"M\u00e9jean","year":"2018","journal-title":"N Engl J Med"},{"key":"2021083104310140900_ref26","doi-asserted-by":"crossref","first-page":"401","DOI":"10.5301\/tj.5000699","article-title":"TARIBO trial: targeted therapy with or without nephrectomy in metastatic renal cell carcinoma: liquid biopsy for biomarkers discovery","volume":"104","author":"Verzoni","year":"2018","journal-title":"Tumori"},{"key":"2021083104310140900_ref27","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jamaoncol.2018.5543","article-title":"Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: The SURTIME randomized clinical trial","volume":"5","author":"Bex","year":"2019","journal-title":"JAMA Oncol"},{"key":"2021083104310140900_ref28","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.juro.2006.06.069","article-title":"Metastatic prostate cancer-does treatment of the primary tumor matter?","volume":"176","author":"Swanson","year":"2006","journal-title":"J Urol"},{"key":"2021083104310140900_ref29","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.eururo.2013.11.012","article-title":"Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study","volume":"65","author":"Culp","year":"2014","journal-title":"Eur Urol"},{"key":"2021083104310140900_ref30","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/01.ju.0000132412.74468.57","article-title":"Failure after primary radiation or surgery for prostate cancer: differences in response to androgen ablation","volume":"172","author":"Swanson","year":"2004","journal-title":"J Urol"},{"key":"2021083104310140900_ref31","volume-title":"Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants with Metastatic Prostate Cancer [Internet]","author":"ClinicalTrials.gov"},{"key":"2021083104310140900_ref32","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2003.04.187","article-title":"Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer","volume":"21","author":"Verwaal","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021083104310140900_ref33","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ejca.2015.09.017","article-title":"Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: a randomised trial","volume":"53","author":"Cashin","year":"2016","journal-title":"Eur J Cancer"},{"key":"2021083104310140900_ref34","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1200\/JCO.20.02447","article-title":"Primary tumor resection plus chemotherapy versus chemotherapy alone for colorectal cancer patients with asymptomatic, synchronous unresectable metastases (JCOG1007; iPACS): a randomized clinical trial","volume":"39","author":"Kanemitsu","year":"2021","journal-title":"J Clin Oncol"},{"key":"2021083104310140900_ref35","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12082306","article-title":"The role of primary tumor resection in colorectal cancer patients with asymptomatic, synchronous, unresectable metastasis: a multicenter randomized controlled trial","volume":"12","author":"Park","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2021083104310140900_ref36","first-page":"1183","article-title":"Gastric cancer with metastases to the distant peritoneum: a 20-year surgical experience","volume":"45","author":"Kikuchi","year":"1998","journal-title":"Hepato-Gastroenterology"},{"key":"2021083104310140900_ref37","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1046\/j.1365-2168.2002.02220.x","article-title":"Value of palliative resection in gastric cancer","volume":"89","author":"Hartgrink","year":"2002","journal-title":"Br J Surg"},{"key":"2021083104310140900_ref38","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1470-2045(15)00553-7","article-title":"Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial","volume":"17","author":"Fujitani","year":"2016","journal-title":"Lancet Oncol"},{"key":"2021083104310140900_ref39","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S1055-3207(03)00026-7","article-title":"The etiology, clinical presentation, and management of pseudomyxoma peritonei","volume":"12","author":"Moran","year":"2003","journal-title":"Surg Oncol Clin N Am"},{"key":"2021083104310140900_ref40","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1080\/02656736.2017.1310938","article-title":"Pseudomyxoma peritonei: natural history and treatment","volume":"33","author":"Mittal","year":"2017","journal-title":"Int J Hyperth"},{"key":"2021083104310140900_ref41","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/00000658-199401000-00009","article-title":"The natural history of surgically treated primary adenocarcinoma of the appendix","volume":"219","author":"Nitecki","year":"1994","journal-title":"Ann Surg"},{"key":"2021083104310140900_ref42","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/jso.21054","article-title":"Consensus statement on the loco-regional treatment of appendiceal mucinous neoplasms with peritoneal dissemination (pseudomyxoma peritonei)","volume":"98","author":"Moran","year":"2008","journal-title":"J Surg Oncol"},{"key":"2021083104310140900_ref43","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1200\/JCO.2011.39.7166","article-title":"Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"30","author":"Chua","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021083104310140900_ref44","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.hoc.2008.11.006","article-title":"Gastrointestinal stromal tumor: a clinical overview","volume":"23","author":"Quek","year":"2009","journal-title":"Hematol Oncol Clin North Am"},{"key":"2021083104310140900_ref45","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11864-015-0384-y","article-title":"The role of surgery in metastatic gastrointestinal stromal tumors","volume":"17","author":"Keung","year":"2016","journal-title":"Curr Treat Options in Oncol"},{"key":"2021083104310140900_ref46","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/00000658-199201000-00010","article-title":"Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging","volume":"215","author":"Ng","year":"1992","journal-title":"Ann Surg"},{"key":"2021083104310140900_ref47","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1245\/s10434-013-3279-9","article-title":"The effects of surgical cytoreduction prior to imatinib therapy on the prognosis of patients with advanced GIST","volume":"20","author":"An","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"2021083104310140900_ref48","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1245\/s10434-014-4360-8","article-title":"Role of surgery in patients with recurrent, metastatic, or unresectable locally advanced gastrointestinal stromal tumors sensitive to imatinib: a retrospective analysis of the Spanish Group for Research on Sarcoma (GEIS)","volume":"22","author":"Rubi\u00f3-Casadevall","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"2021083104310140900_ref49","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.surg.2017.05.030","article-title":"Expanded criteria for debulking of liver metastasis also apply to pancreatic neuroendocrine tumors","volume":"163","author":"Morgan","year":"2018","journal-title":"Surgery"},{"key":"2021083104310140900_ref50","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.hpb.2017.08.039","article-title":"Cytoreductive debulking surgery among patients with neuroendocrine liver metastasis: a multi-institutional analysis","volume":"20","author":"Ejaz","year":"2018","journal-title":"HPB (Oxford)"},{"key":"2021083104310140900_ref51","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1072-7515(03)00230-8","article-title":"Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival","volume":"197","author":"Sarmiento","year":"2003","journal-title":"J Am Coll Surg"},{"key":"2021083104310140900_ref52","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.surg.2018.04.070","article-title":"Effective cytoreduction can be achieved in patients with numerous neuroendocrine tumor liver metastases (NETLMs)","volume":"165","author":"Scott","year":"2019","journal-title":"Surgery"},{"key":"2021083104310140900_ref53","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1097\/SLA.0b013e3181656d32","article-title":"Association of surgery with improved survival in stage IV breast cancer patients","volume":"247","author":"Blanchard","year":"2008","journal-title":"Ann Surg"},{"key":"2021083104310140900_ref54","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1001\/jamasurg.2015.4539","article-title":"Initial surgery and survival in stage IV breast cancer in the United States, 1988\u20132011","volume":"151","author":"Thomas","year":"2016","journal-title":"JAMA Surg"},{"key":"2021083104310140900_ref55","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1245\/s10434-020-08310-2","article-title":"The impact of primary tumor surgery on survival in HER2 positive stage IV breast cancer patients in the current era of targeted therapy","volume":"27","author":"Mudgway","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"2021083104310140900_ref56","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1245\/s10434-018-6494-6","article-title":"Randomized trial comparing resection of primary tumor with no surgery in stage IV breast cancer at presentation: Protocol MF07-01","volume":"25","author":"Soran","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"2021083104310140900_ref57","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1097\/SLA.0000000000002771","article-title":"Impact of breast surgery in primary metastasized breast cancer: outcomes of the prospective randomized phase III ABCSG-28 POSYTIVE trial","volume":"269","author":"Fitzal","year":"2019","journal-title":"Ann Surg"},{"key":"2021083104310140900_ref58","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/S1470-2045(15)00135-7","article-title":"Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial","volume":"16","author":"Badwe","year":"2015","journal-title":"Lancet Oncol"},{"key":"2021083104310140900_ref59","doi-asserted-by":"crossref","first-page":"LBA2","DOI":"10.1200\/JCO.2020.38.18_suppl.LBA2","article-title":"A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: a trial of the ECOG-ACRIN Research Group (E2108)","volume":"38","author":"Khan","year":"2020","journal-title":"J Clin Oncol"},{"key":"2021083104310140900_ref60","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1056\/NEJM198503143121102","article-title":"Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation","volume":"312","author":"Fisher","year":"1985","journal-title":"N Engl J Med"},{"key":"2021083104310140900_ref61","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1093\/jjco\/hys120","article-title":"A randomized controlled trial comparing primary tumour resection plus systemic therapy with systemic therapy alone in metastatic breast cancer (PRIM-BC): Japan Clinical Oncology Group Study JCOG1017","volume":"42","author":"Shien","year":"2012","journal-title":"Jpn J Clin Oncol"},{"key":"2021083104310140900_ref62","volume-title":"WHO Classification and Grading of Tumours of the Central Nervous System","author":"Louis","year":"2016"},{"key":"2021083104310140900_ref63","volume-title":"Meningiomas","author":"Prayson","year":"2009"},{"key":"2021083104310140900_ref64","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"2021083104310140900_ref65","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S1470-2045(11)70196-6","article-title":"Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial","volume":"12","author":"Senft","year":"2011","journal-title":"Lancet Oncol"},{"key":"2021083104310140900_ref66","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1200\/JCO.2011.38.4818","article-title":"Impact of intraoperative stimulation brain mapping on glioma surgery outcome: a meta-analysis","volume":"30","author":"De Witt Hamer","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021083104310140900_ref67","first-page":"1444","article-title":"Surgery for metastatic pleural extension of non-small-cell lung cancer","volume":"40","author":"Mordant","year":"2011","journal-title":"Eur J Cardiothorac Surg"},{"key":"2021083104310140900_ref68","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.jtcvs.2017.09.162","article-title":"Lung adenocarcinoma with intraoperatively diagnosed pleural seeding: Is main tumor resection beneficial for prognosis?","volume":"155","author":"Li","year":"2018","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2021083104310140900_ref69","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1097\/JTO.0000000000000554","article-title":"Surgical intervention for non-small-cell lung cancer patients with pleural carcinomatosis: results from the Japanese lung cancer registry in 2004","volume":"10","author":"Iida","year":"2015","journal-title":"J Thorac Oncol"},{"key":"2021083104310140900_ref70","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1055\/s-0035-1564928","article-title":"Surgical outcomes after pulmonary resection for non-small cell lung cancer with localized pleural seeding first detected during surgery","volume":"66","author":"Yun","year":"2018","journal-title":"Thorac Cardiovasc Surg"},{"key":"2021083104310140900_ref71","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1097\/JTO.0000000000000673","article-title":"The IASLC Lung Cancer Staging Project: proposals for the Revision of the M Descriptors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer","volume":"10","author":"Eberhardt","year":"2015","journal-title":"J Thorac Oncol"},{"key":"2021083104310140900_ref72","doi-asserted-by":"crossref","first-page":"949","DOI":"10.3892\/mco.2013.164","article-title":"Outcome of platinum-based chemotherapy for non-small-cell lung cancer patients with pleural dissemination detected during surgery","volume":"1","author":"Kimura","year":"2013","journal-title":"Mol Clin Oncol"},{"key":"2021083104310140900_ref73","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/0003-4975(91)90478-9","article-title":"Thymoma: results of 241 operated cases","volume":"51","author":"Maggi","year":"1991","journal-title":"Ann Thorac Surg"},{"key":"2021083104310140900_ref74","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0003-4975(03)00555-1","article-title":"Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan","volume":"76","author":"Kondo","year":"2003","journal-title":"Ann Thorac Surg"},{"key":"2021083104310140900_ref75","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.ejso.2006.03.049","article-title":"Debulking surgery for advanced thymoma","volume":"32","author":"Liu","year":"2006","journal-title":"Eur J Surg Oncol"},{"key":"2021083104310140900_ref76","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1093\/ejcts\/ezu277","article-title":"A meta-analysis of debulking surgery versus surgical biopsy for unresectable thymoma","volume":"47","author":"Hamaji","year":"2015","journal-title":"Eur J Cardiothorac Surg"},{"key":"2021083104310140900_ref77","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejcts.2009.02.019","article-title":"Early Masaoka stage and complete resection is important for prognosis of thymic carcinoma: a 20-year experience at a single institution","volume":"36","author":"Lee","year":"2009","journal-title":"Eur J Cardiothorac Surg"},{"key":"2021083104310140900_ref78","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ejcts\/ezv239","article-title":"Long-term outcome and prognostic factors of surgically treated thymic carcinoma: results of 306 cases from a Japanese Nationwide Database Study","volume":"49","author":"Hishida","year":"2016","journal-title":"Eur J Cardiothorac Surg"},{"key":"2021083104310140900_ref79","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1200\/JCO.2010.32.9607","article-title":"Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma","volume":"29","author":"Lemma","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021083104310140900_ref80","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1097\/JTO.0000000000000362","article-title":"Phase II study of Amrubicin combined with carboplatin for thymic carcinoma and invasive thymoma: North Japan Lung Cancer group study 0803","volume":"9","author":"Inoue","year":"2014","journal-title":"J Thorac Oncol"},{"key":"2021083104310140900_ref81","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1634\/theoncologist.2017-0586","article-title":"Prognostic factors and efficacy of first-line chemotherapy in patients with advanced thymic carcinoma: a retrospective analysis of 286 patients from NEJ023 study","volume":"23","author":"Ko","year":"2018","journal-title":"Oncologist"},{"key":"2021083104310140900_ref82","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/j.jtho.2018.08.001","article-title":"Surgery in malignant pleural mesothelioma","volume":"13","author":"Bueno","year":"2018","journal-title":"J Thorac Oncol"},{"key":"2021083104310140900_ref83","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.21037\/tlcr.2020.01.08","article-title":"Surgery for pleural mesothelioma, when it is indicated and why: arguments against surgery for malignant pleural mesothelioma","author":"Woodard","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"2021083104310140900_ref84","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(11)70149-8","article-title":"Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study","volume":"12","author":"Treasure","year":"2011","journal-title":"Lancet Oncol"},{"key":"2021083104310140900_ref85","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.lungcan.2013.11.026","article-title":"A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma","volume":"83","author":"Cao","year":"2014","journal-title":"Lung Cancer"},{"key":"2021083104310140900_ref86","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.athoracsur.2014.09.056","article-title":"Meta-analysis of survival after pleurectomy decortication versus extrapleural pneumonectomy in mesothelioma","volume":"99","author":"Taioli","year":"2015","journal-title":"Ann Thorac Surg"},{"key":"2021083104310140900_ref87","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/1097-0142(197601)37:1<20::AID-CNCR2820370104>3.0.CO;2-Z","article-title":"Combination radical surgery and multiple sequential chemotherapy for the treatment of advanced carcinoma of the testis (stage III)","volume":"37","author":"Merrin","year":"1976","journal-title":"Cancer"},{"key":"2021083104310140900_ref88","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0022-5347(17)58438-4","article-title":"Treatment of recurrent and widespread testicular tumor by radical reductive surgery and multiple sequential chemotherapy","volume":"117","author":"Merrin","year":"1977","journal-title":"J Urol"},{"key":"2021083104310140900_ref89","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1158\/2159-8290.CD-15-0439","article-title":"Evolutionary determinants of cancer","volume":"5","author":"Greaves","year":"2015","journal-title":"Cancer Discov"},{"key":"2021083104310140900_ref90","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","article-title":"Clonal heterogeneity and tumor evolution: past, present, and the future","volume":"168","author":"McGranahan","year":"2017","journal-title":"Cell"},{"key":"2021083104310140900_ref91","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa1616288","article-title":"Tracking the evolution of non-small-cell lung cancer","volume":"376","author":"Jamal-Hanjani","year":"2017","journal-title":"N Engl J Med"},{"key":"2021083104310140900_ref92","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nrc.2017.126","article-title":"Genetic insights into the morass of metastatic heterogeneity","volume":"18","author":"Hunter","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"2021083104310140900_ref93","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: Long-term results of a multi-institutional, phase II, randomized study","volume":"37","author":"Gomez","year":"2019","journal-title":"J Clin Oncol"},{"key":"2021083104310140900_ref94","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s13014-020-01651-y","article-title":"The value of local consolidative therapy in osimertinib-treated non-small cell lung cancer with oligo-residual disease","volume":"15","author":"Zeng","year":"2020","journal-title":"Radiat Oncol"},{"key":"2021083104310140900_ref95","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/nature22079","article-title":"T-cell invigoration to tumour burden ratio associated with anti-PD-1 response","volume":"545","author":"Huang","year":"2017","journal-title":"Nature"},{"key":"2021083104310140900_ref96","doi-asserted-by":"crossref","first-page":"4960","DOI":"10.1158\/1078-0432.CCR-17-2386","article-title":"Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab","volume":"24","author":"Joseph","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2021083104310140900_ref97","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-52913-z","article-title":"A rationale for surgical debulking to improve anti-PD1 therapy outcome in non-small cell lung cancer","volume":"9","author":"Guisier","year":"2019","journal-title":"Sci Rep"},{"key":"2021083104310140900_ref98","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1902626","article-title":"Secondary surgical cytoreduction for recurrent ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N Engl J Med"},{"key":"2021083104310140900_ref99","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1471-2407-14-22","article-title":"Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomised controlled study","volume":"14","author":"Laar","year":"2014","journal-title":"BMC Cancer"},{"key":"2021083104310140900_ref100","doi-asserted-by":"crossref","first-page":"6001","DOI":"10.1200\/JCO.2020.38.15_suppl.6001","article-title":"A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1\/SGOG-OV2","volume":"38","author":"Zang","year":"2020","journal-title":"J Clin Oncol"},{"key":"2021083104310140900_ref101","author":"ClinicalTrials.gov"},{"key":"2021083104310140900_ref102","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/1471-2407-12-142","article-title":"Resection of the primary tumour versus no resection prior to systemic therapy in patients with colon cancer and synchronous unresectable metastases (UICC stage IV): SYNCHRONOUS--a randomised controlled multicentre trial (ISRCTN30964555)","volume":"12","author":"Rahbari","year":"2012","journal-title":"BMC Cancer"},{"key":"2021083104310140900_ref103","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1186\/1471-2407-14-741","article-title":"The CAIRO4 study: the role of surgery of the primary tumour with few or absent symptoms in patients with synchronous unresectable metastases of colorectal cancer--a randomized phase III study of the Dutch Colorectal Cancer Group (DCCG)","volume":"14","author":"t Lam-Boer","year":"2014","journal-title":"BMC Cancer"},{"key":"2021083104310140900_ref104","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s00384-017-2827-3","article-title":"Impact of resection versus no resection of the primary tumor on survival in patients with colorectal cancer and synchronous unresectable metastases: protocol for a randomized multicenter study (CR4)","volume":"32","author":"Biondo","year":"2017","journal-title":"Int J Color Dis"},{"key":"2021083104310140900_ref105","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1186\/s12885-019-5640-2","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy versus palliative systemic chemotherapy in stomach cancer patients with peritoneal dissemination, the study protocol of a multicentre randomised controlled trial (PERISCOPE II)","volume":"19","author":"Koemans","year":"2019","journal-title":"BMC Cancer"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/51\/9\/1349\/40082929\/hyab107.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/51\/9\/1349\/40082929\/hyab107.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T00:32:37Z","timestamp":1630369957000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/51\/9\/1349\/6319623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,12]]},"references-count":105,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,7,12]]},"published-print":{"date-parts":[[2021,8,30]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyab107","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,9]]},"published":{"date-parts":[[2021,7,12]]}}}